1093798-74-3

Basic information

• Product Name: ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate
• Synonyms: ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate
• CAS NO: 1093798-74-3
• Molecular Weight: 283.281
• Mol File: 1093798-74-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate(1093798-74-3)
• EPA Substance Registry System: ethyl 4-(2-methoxy-5-nitrophenoxy)butanoate(1093798-74-3)

Safety Data

• Hazardous Substances Data: 1093798-74-3(Hazardous Substances Data)

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 636-93-1 5-nitroguaiacol 
• 3153-36-4 4-chloro-butyric acid ethyl ester 

Downstream Products

• 1093798-77-6 C₂₇H₃₆N₆O₇ 
• 1093798-78-7 C₂₂H₂₈N₆O₅ 
• 1093798-76-5 C₁₁H₁₅NO₄*ClH 
• 1093798-75-4 C₁₃H₁₉NO₄*ClH 

Relevant articles and documents

Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer

Fifty-eight quinazoline-based compounds were designed and synthesized based on the structural optimizations from the lead compound 23bb in an attempt to search for more potent dual HDAC1 and HDAC6 inhibitors. Among them, 32c (HDAC1, IC50?=?31.1

PYRROLOPYRIMIDINES

The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.